Freeze-dried kit formulation and physicochemical assessment of a daratumumab-based radiopharmaceutical
Acta Pharmaceutica · 01.06.2026 · 76 (2) · 1-16
DOI: 10.2478/acph-2026-0013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica, online erschienen am 30.06.2026. Verfasst von Paulina Apostolova und 10 weiteren Autor:innen. Beteiligte Einrichtung: 1Faculty of Medical Sciences, Goce Delcev University, 2000Stip, North Macedonia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Radiopharmaceuticals, Immunoconjugates. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Daratumumab is a fully human anti-CD38 monoclonal antibody with strong potential as a targeting vector for therapeutic radionuclides. This study aimed to develop a freeze-dried daratumumab immunoconjugate kit by selecting a suitable chelator (DOTA-NHS, p -SCN-Bn-DOTA, or p -SCN-Bn-1B4M-DTPA) for the 177 Lu-labelling, optimising the freeze-drying formulation, and evaluating the physicochemical properties and purity profiles. Conjugation performed in carbonate buffer at elevated temperature enhanced chelator incorporation and supported the selection of daratumumab- p -SCN-Bn-DOTA as the most suitable candidate, achieving radiolabelling yield up to 99.8 % without additional purification. Among the evaluated freeze-dried formulations, a saline-based, buffer-free sucrose-mannitol formulation containing polysorbate 20 (S.F5) provided the most favourable characteristics, including minimal residual moisture and the highest monomer purity with non-detectable HMWS species under the applied SE-HPLC conditions. ATR-FTIR and Raman spectroscopy confirmed preservation of the antibody structural integrity after conjugation and freeze-drying. In an in vitro study using human serum, [ 177 Lu]Lu-daratumumab- p -SCNBn-DOTA maintained higher radiochemical purity for 168 h than [ 177 Lu]Lu-daratumumab- p -SCN-Bn-1B4MDTPA, indicating greater stability. These results support the feasibility of a ready-to-use freeze-dried daratumumab- p -SCN-Bn-DOTA kit for the 177 Lu-labelling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1Faculty of Medical Sciences, Goce Delcev University, 2000Stip, North Macedonia.
- 2University Institute of Positron Emission Tomography, 1000Skopje, North Macedonia.
- 3Research Centre for Genetic Engineering and Biotechnology "Georgi D Efremov" Macedonian Academy of Sciences and Arts 1000 Skopje, North Macedonia.
- 4Institute of Chemistry, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University in Skopje, 1000Skopje, North Macedonia.
- 5Replek Farm Ltd., 1000Skopje, North Macedonia.
- 7Quality Assurance, ALKALOID AD Skopje, 1000 Skopje, North Macedonia.
ORCID-Profile: Paulina Apostolova, Marija Atanasova Lazareva, Katarina Davalieva, Marija Arev, Dino Karpicarov, Petre Makreski, Irena Slaveska Spirevska, Ivana Mitrevska, Aleksandar Dimovski, Sanja Vranješ-Đurić, Emilija Janevik-Ivanovska
Zitieren
APA
Apostolova, P., Lazareva, M. A., Davalieva, K., Arev, M., Karpicarov, D., Makreski, P., Spirevska, I. S., Mitrevska, I., Dimovski, A., Vranješ-Đurić, S., & Janevik-Ivanovska, E. (2026). Freeze-dried kit formulation and physicochemical assessment of a daratumumab-based radiopharmaceutical. Acta Pharmaceutica, 76(2), 1-16. https://doi.org/10.2478/acph-2026-0013
Vancouver
Apostolova P, Lazareva MA, Davalieva K, Arev M, Karpicarov D, Makreski P, et al. Freeze-dried kit formulation and physicochemical assessment of a daratumumab-based radiopharmaceutical. Acta Pharmaceutica. 2026;76(2):1-16. doi:10.2478/acph-2026-0013
BibTeX
@article{Apostolova2026,
author = {Apostolova, Paulina and Lazareva, Marija Atanasova and Davalieva, Katarina and Arev, Marija and Karpicarov, Dino and Makreski, Petre and Spirevska, Irena Slaveska and Mitrevska, Ivana and Dimovski, Aleksandar and Vranješ-Đurić, Sanja and Janevik-Ivanovska, Emilija},
title = {Freeze-dried kit formulation and physicochemical assessment of a daratumumab-based radiopharmaceutical},
journal = {Acta Pharmaceutica},
year = {2026},
volume = {76},
number = {2},
pages = {1--16},
doi = {10.2478/acph-2026-0013}
}
EUVIMED